NewLink Looks To Nix Investor Suit Over Cancer Drug, Again
By Rachel Graf ( August 1, 2018, 4:10 PM EDT) -- Biopharmaceutical company NewLink Genetics Corp. urged a New York federal court Tuesday to dismiss for a second time a proposed investor class action alleging executives' misrepresentations about a pancreatic cancer treatment artificially inflated stock prices, saying the court already determined the statements were "non-actionable opinions."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.